Tag
This study reveals significant racial differences in atherosclerotic cardiovascular disease risk among women with PMOS, highlighting that social determinants of health influence these disparities, particularly among Black women.
This cohort study links postpartum blood pressure at 6 weeks following hypertensive pregnancy disorders with a doubled risk of future cardiovascular disease, highlighting a crucial preventive care window.
This study reveals that various combinations of daily step counts and stepping intensity independently reduce all-cause and cardiovascular mortality, highlighting the importance of personalized physical activity strategies.
An expert consensus provides practical, evidence-informed guidance for clinicians to protect people with cardiovascular disease from rising heat extremes, focusing on prevention, medication review, cooling strategies, and health-system prep
A large cohort study highlights how acquired cardiovascular risk factors significantly influence late mortality in adults with congenital heart disease, underscoring the need for integrated care strategies.
Occupational exposure to both dust and fumes significantly increases the risk of future respiratory exacerbations, atherosclerotic cardiovascular disease, and pneumonia in smokers and former smokers, underscoring the need for targeted preve
Functional hypothalamic amenorrhea (FHA) in mid-adulthood is linked to increased coronary heart disease risk and type 2 diabetes, independent of traditional factors, highlighting menstrual irregularities as early cardiometabolic risk indica
Most heart failure patients harbor multiple cardiovascular-kidney-metabolic conditions, which independently escalate mortality and readmission risk, especially in HFrEF, underscoring the need for integrated management strategies tailored by
In the SELECT trial, baseline clinical factors poorly predicted peak body weight loss with semaglutide, highlighting the role of sex and dosage but underscoring substantial unexplained variability in patient response.
Declines in frailty, intrinsic capacity, and physical quality of life occur years before cardiovascular events, highlighting a prolonged window for early intervention in older adults.
Younger age at type 1 diabetes diagnosis significantly increases risks of mortality, cardiovascular, and kidney complications; each additional year delay in onset reduces these risks. This review synthesizes nationwide cohort findings and c
Semaglutide demonstrates consistent cardiovascular benefits and safety across frailty levels in overweight adults with cardiovascular disease, enhancing quality of life and frailty status without increased adverse events.
Subclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction and
Long-term cumulative exposure to wildfire smoke PM2.5 significantly increases cardiovascular hospitalizations among U.S. older adults, with notable risks in ischemic heart disease and arrhythmias, highlighting the need for targeted public h
Clonal hematopoiesis of indeterminate potential (CHIP) poses a novel cardiovascular risk. This article explores challenges and strategies for designing cardiovascular outcomes trials tailored to CHIP’s genetic heterogeneity and clinical com
This national English study reveals a significant increase in pre-existing cardiovascular disease among patients at cancer diagnosis over two decades, projecting nearly half will have cardiovascular comorbidities by 2050, underlining urgent
Long-term intensive BP control led by trained nonphysician community providers significantly lowers cardiovascular risk over 7 years, with benefits persisting 3 years post-intervention in rural China.
Single-cell multi-omics profiling reveals novel immune signatures linked to coronary artery disease and cardiovascular outcomes, independent of traditional inflammatory markers, offering new avenues for risk stratification and personalized
In the SELECT trial, semaglutide significantly lowered hsCRP levels and major cardiovascular events in patients with established atherosclerotic cardiovascular disease and overweight or obesity, suggesting inflammation reduction as a possib
Changes in NT-proBNP levels over three years define heart stress status, which improves cardiovascular and mortality risk prediction in older adults without prior CVD, underscoring its utility in clinical risk stratification.
